The Print on MSN
Budget cuts import costs of 17 cancer & 7 rare disease drugs. Why it offers little relief to patients
Cancer imposes catastrophic health expenditure in India, with medicines constituting over 60% of out-of-pocket expenditure.
The move can significantly lower out‑of‑pocket burdens for families, given that India’s health insurance coverage for ...
HER2 and ABCC1 are identified as significant transcriptomic predictors of overall survival in patients treated with T-DXd. A large-scale analysis reveals novel predictors of survival and resistance ...
Researchers have revealed how patients with metastatic breast cancer develop resistance to Enhertu treatment.
Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine ...
MedPage Today on MSN
Novel treatments for gastric cancer
Immunotherapy, targeted treatments, HIPEC, and new delivery options ...
In the fourth quarter of 2025, Samsung Bioepis achieved a consolidated revenue of KRW 429.4 billion with an operating profit of KRW 29.2 billion. Revenue and operating profit based on product sales ...
Japanese pharma Daiichi Sankyo (TSE: 4568) and British partner AstraZeneca (LSE: AZN) said Enhertu (trastuzumab deruxtecan) ...
Daiichi Sankyo and AstraZeneca’s Enhertu has received approval from China’s NMPA for adult patients with locally advanced or ...
Daiichi Sankyo & AstraZeneca’s Enhertu approved in China as first and only HER2 directed ADC for second-line treatment of patients with HER2 positive metastatic gastric cancer ...
AstraZeneca plans to delist from Nasdaq and move to the NYSE, while its breast cancer drug Enhertu enters European regulatory review after strong trial results.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results